In this randomized controlled trial, among patients with early-stage triple-negative breast cancer (TNBC), the addition of ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the clinical ...

Vibostolimab is being evaluated as an investigational fixed-dose combination with pembrolizumab (Keytruda) in the KeyVibe programme. Favezelimab is being evaluated as an investigational fixed-dose ...

New research revealed tumor mutational burden was linked to improved event-free survival with pembrolizumab in early TNBC, ...

Merck & Co Inc (NYSE:MRK) revealed that it would discontinue the clinical development programs for vibostolimab and ...

Josep M. Llovet, MD, PhD, describes the phase 3 LEAP-012 clinical study, including its methods, design, and enrollment ...

Adding pembrolizumab to THP improved pCR rates in patients with HER2-positive breast cancer in the phase 2 NeoHIP trial.

Teos Therapeutics has potential lung cancer treatment despite issues and strong financial position. Read here to know why we ...

Lenvatinib plus pembrolizumab did not provide benefits over chemotherapy in the overall study cohort, but the combination did provide benefits in subgroups of patients.

In an interview with Targeted Oncology, Jaime Merchan, MD, delved into data from the LITESPARK-013 trial evaluating ...

Merck (MRK) announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an ...

The addition of atezolizumab to neoadjuvant chemotherapy failed to significantly improve event-free survival in patients with ...